Deal News
Resonance Health agrees to acquire TrialsWest
Australian healthcare technology and services company Resonance Health has agreed to acquire 100% of clinical research centre TrialsWest for a…
Seyltx buys Algernon’s Phase II chronic cough therapy
US-based Seyltx has closed an agreement to acquire Algernon Pharmaceuticals’ chronic cough therapy, ifenprodil (NP-120). Algernon received a purchase price…
PCM Trials acquires EmVenio to boost decentralised clinical trials
PCM Trials has acquired US-based EmVenio Research, a community-based clinical trial site provider equipped with mobile research units, to design…
Signal: Tweets of the week focus on Eli Lilly’s most recent acquisitions
Eli Lilly continues to make news by announcing its complete acquisition of the Massachusetts-headquartered Sigilon on 14 August. The deal…
BioVaxys Technology buys clinical studies management company TAETSoftware
BioVaxys Technology has acquired clinical studies management company TAETSoftware (TAETCo), which develops and commercialises the Trial Adverse Events Tracker (TAET)…
IGM and ADC enter clinical trial partnership deal for lymphoma treatment
IGM Biosciences has signed a clinical trial partnership and supply agreement with ADC Therapeutics to analyse the combination of imvotamab and…
Erasca and Pfizer enter trial partnership for palbociclib
Erasca and Pfizer have entered a clinical trial partnership and supply agreement for palbociclib (Ibrance), an inhibitor of CDK4/6. Under the collaboration, the companies…
GSK and Tempus partner to boost clinical trial design
GSK has signed a three-year partnership agreement with Tempus to enhance clinical trial design, expedite subject enrolment and detect drug targets. Under the…
Lightship and Acclinate to boost trial access for underrepresented people
Lightship has entered a collaboration with Acclinate to boost access and engagement in clinical trials for populations which are underrepresented.…
TILT Biotherapeutics and MSD partner for lung cancer treatment trial
TILT Biotherapeutics and MSD (Merck) have entered a clinical trial collaboration and supply agreement for an oncolytic immunotherapy candidate, TILT-123, for non-small cell lung…
